Clinical Trial Update: Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 double-masked study of PG324 ophthalmic solution in open-angle glaucoma and ocular hypertension has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• PG324 ophthalmic solution (PG324)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2019-06-04